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Identification of Histamine H3 
Receptor Ligands Using a New 
Crystal Structure Fragment-based 
Method
Ida Osborn Frandsen, Michael W. Boesgaard, Kimberley Fidom, Alexander S. Hauser  ,  
Vignir Isberg  , Hans Bräuner-Osborne  , Petrine Wellendorph & David E. Gloriam  
Virtual screening offers an efficient alternative to high-throughput screening in the identification of 
pharmacological tools and lead compounds. Virtual screening is typically based on the matching of 
target structures or ligand pharmacophores to commercial or in-house compound catalogues. This 
study provides the first proof-of-concept for our recently reported method where pharmacophores are 
instead constructed based on the inference of residue-ligand fragments from crystal structures. We 
demonstrate its unique utility for G protein-coupled receptors, which represent the largest families of 
human membrane proteins and drug targets. We identified five neutral antagonists and one inverse 
agonist for the histamine H3 receptor with potencies of 0.7–8.5 μM in a recombinant receptor cell-based 
inositol phosphate accumulation assay and validated their activity using a radioligand competition 
binding assay. H3 receptor antagonism is of large therapeutic value and our ligands could serve as 
starting points for further lead optimisation. The six ligands exhibit four chemical scaffolds, whereof 
three have high novelty in comparison to the known H3 receptor ligands in the ChEMBL database. The 
complete pharmacophore fragment library is freely available through the GPCR database, GPCRdb, 
allowing the successful application herein to be repeated for most of the 285 class A GPCR targets. The 
method could also easily be adapted to other protein families.
G protein-coupled receptors (GPCRs) are membrane proteins activated by many diverse ligands including pho-
tons, ions, neurotransmitters, lipids, carbohydrates, nucleotides, amino acids, peptides (e.g. hormones) and pro-
teins1. The GPCR family is with its ~800 genes among the largest families in the human genome2 and involved in 
most physiological processes3, 4. Their regulation of pathophysiology in diverse disease areas and accessibility at 
the cell surface have earned them a key role in medicine: more than 30% of the drug on the market target GPCRs5. 
59 GPCRs have been drugged with small molecules6; the vast majority binding within a structurally conserved 
pocket within the transmembrane heptahelical bundle (7TM)7. Modelling of ligand-receptor complexes can now 
be performed with higher accuracy as a result of the increasing number of GPCR crystal structures, and has been 
evaluated in three community-wide ‘GPCR Dock’ assessments8–10.
Virtual screening is an efficient alternative to high-throughput screening to identify new ligands. This entails 
a preceding screening in silico of commercial or in-house compound catalogues against a target structure11–13 or 
ligand pharmacophore14, 15. We recently described the development of a new chemogenomics method to generate 
pharmacophores for GPCRs16. The method is based on the extraction of a reference library of crystal structure 
fragments, which are interacting moiety-residue pairs. The complete library of moiety-residue pairs has been 
made available through the GPCR database, GPCRdb17, 18. Although specific for GPCR ligand discovery, this is 
analogous to general resources that extract the residue-ligand fragment information from crystal structures19–21. 
Here, we describe the first application of this method to identify new histamine H3 receptor ligands.
The H3 receptor is found mainly in the CNS and is implicated in cognition, sleep regulation, feeding, memory, 
nociception and the sleep/wake cycle22–24. It functions both as a presynaptic autoreceptor, as well as a regulator of 
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the release of other neurotransmitters; such as serotonin, dopamine and acetylcholine; which may be co-released 
with GABA in some neurons to control wakefulness25. H3 has a remarkably high level of constitutive activity26 
also in vivo27, and many of the classical H3 receptor antagonists have recently been found to be inverse agonists22. 
H3 is coupled to the Gi/o class of G proteins, leading to inhibition of the adenylyl cyclase and decreased cAMP 
generation28, 29. The H3 receptor has shown a potential therapeutic use in a number of CNS indications; ADHD, 
cognitive disorders, epilepsy, narcolepsy, neurodegeneration and pain30, 31; as well as in treating alcohol32 and 
eating33 behaviours (for general reviews see refs 22–24).
Results
Pharmacophore model and virtual screening hits. The transmembrane domain of GPCRs can be 
aligned both in structure and sequence to identify the corresponding residue positions, which are below indexed 
using the GPCRdb scheme34. This is an evolution of the Ballesteros-Weinstein scheme35 modified to take into 
account helical bulges and constrictions observed in GPCR crystal structures. Matching of the H3 receptor 
sequence against our library of crystal structure fragments identified five conserved residues: W3.28, D3.32, 
Y3.33, Y6.51 and W6.48. A sixth residue, E5.46x461, could be added from reference ligands matched to the phar-
macophore and docked into a H3 structure model. Apart from the residue, each fragment also has an interacting 
ligand moiety onto which the pharmacophore elements are placed. Figure 1 shows the final pharmacophore 
constructed from all the retrieved fragments, which are listed in Supplementary Table 1. The pharmacophore 
contains three hydrogen bond donor (D1-3), three cation (P4-6), three aromatic (R7, R9 and R10) and one dual 
aromatic/hydrophobic (R8 and R10) elements. The screening of this pharmacophore and subsequent hit cluster-
ing resulted in 44 compounds selected for purchase (Supplementary Chart 1).
The majority of the pharmacophore hits have long linkers between the two essential elements, the cationic 
P5 and aromatic R10, which is typical for antagonistic rather than agonistic aminergic ligands. Apart from the 
essential match to P5 (the site of the archetypical aminergic ligand cation interacting with the conserved D3.32), 
as many as 31 hits also matched P6, whereof only two matched the third element P4. The additional match to P6 
is significant, as this feature, or rather its interacting residue E5.46x461, is not shared by the H1–2 receptors and 
therefore is likely to contribute to selectivity. Apart from the essential match to the aromatic element R10, about 
half (21) and a third (15) of the hits also matched R7 and R9, respectively (5 matched both). In contrast, R8 that is 
a dual hydrophobic/aromatic element matched only 3 aromatic moieties, but 23 hydrophobic. Finally, the number 
of matches for the hydrogen bonding elements reflected that of their adjacent cationic features, with 39, 33 and 5 
matches for D3, D2 and D1, respectively.
Histamine H3 receptor assay validation. As shown in Fig. 2, the co-expression of H3 receptor and the 
chimeric G protein Gqi5 in tsA cells allowed for the generation of a histamine concentration-response curve in 
the IP-One assay with an EC50 value of 150 nM (pEC50 = 6.8 ± 0.4; n = 12). Furthermore, the reference antagonist 
thioperamide gave an IC50 value of 62 nM (pIC50 = 7.2 ± 0.3; n = 4), in the presence of EC80 of histamine (data not 
shown). Previous studies also using Gqi5 co-expression in HEK-derived cells reported values of 21.8 nM36 and 
151 nM37 for histamine and thioperamide in mouse and human H3 receptors, respectively. The differences in EC50 
and IC50; about 7-fold and 2-fold, respectively; may be attributed to differences in assay conditions (IP1 accumu-
lation versus Ca2+ release), species used, and/or differences in expression system. To validate the suitability of the 
assay for high-throughput screening, the Z′-factors38 were determined, as described in methods. The Z′-factors 
determined were 0.5 and 0.3 for agonism and antagonism modes, respectively, which is indicative of an acceptable 
separation between the positive and the negative controls38. Thus, the assay was found to have adequate sensitiv-
ity, reproducibility and accuracy for the intended compound screening.
Novel H3 receptor ligands. The first pharmacological assaying evaluated the selected 44 pharmacophore 
screening hits, and resulted in four antagonist hits; 21, 34, 35, 42. The second pharmacological assaying con-
cerned 32 analogues of the four first hits (21: 45–48, 34: 49–54, 35: 55–72 and 42: 73–76), and resulted in four 
Figure 1. Histamine H3 receptor pharmacophore model used in the virtual screening for new ligands. The 
pharmacophore was based on a receptor residue – ligand moiety fragment library derived from GPCR crystal 
structures (Supplementary Table 1), and built with Phase61. The pharmacophore elements include three 
hydrogen bond donor (D1-3, light blue), three cation (P4-6, blue), three aromatic (R7, R9 and R10; orange) and 
one dual aromatic/hydrophobic (R8, orange) features.
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new antagonists 46, 57, 67 and 76. Three seemingly active compounds from the first screen were excluded due to 
borderline activity (20) or an azaindolizine substructure (9 and 44), which can be fluorescent leading to a false 
positive response. Furthermore, after the secondary screen, compounds 21, 42, 64, 68 and 75 were excluded 
because of the more stringent IC50 cut-off of 10 µM (Supplementary Table 2). The three antagonists 34, 67 and 
76 displayed inhibition below the basal level, and were therefore also tested as inverse agonists. Inverse agonistic 
activity was shown for 76 with an IC50 of 4.2 µM but not for 34 and 67. In summary, we identified five antagonists 
(34, 35, 46, 57 and 67) (Fig. 3A) and one inverse agonist (76) (Fig. 3B), with IC50 values ranging 0.66–8.5 µM 
(Table 1).
To confirm the results obtained from the functional studies, the six compounds (34, 35, 46, 57, 67 and 76) 
were also examined in a [3H]N-α-methylhistamine radioligand competition binding assay (Fig. 4A). Their Ki 
values ranged between 1.59–6.07 µM (Table 1) and were generally in good agreement with the potency observed 
in the functional study (Fig. 4B).
We assessed the novelty of the ligand structures by identifying the most similar H3 ligands in ChEMBL 
(Table 1). Ligand structures can be considered novel if their fingerprints have a Tanimoto Coefficient below 0.439. 
35 is just above this cut-off and 57 and 67 come close, whereas 34, 46 and 76 are quite dissimilar to the known 
H3 ligands. The three least novel structures, share a fused triple ring core that in 35 contains a central imidazole, 
which is shared by histamine and many surrogate ligands. In contrast, the three novel ligands 34, 46 and 76, con-
tain scaffolds that are distinct also among the herein described hit compounds. Apart from fused ring systems, 
all six ligands contain an amine that is positive ionisable, which was an essential match in the pharmacophore 
screening. Furthermore, 76 contains an amine β-hydroxyl and 46 a 4-aryl-piperidine that are known to be com-
mon functionalities in many aminergic and GPCR40, 41 ligands, respectively.
Histamine receptor binding site selectivity hotspots. Whereas experimental ligand selectivity was 
outside of the scope of this study, we compared the sequences and structures of the four histamine receptor 
subtypes to provide a rationale for future optimisation efforts. This showed that the H1, H2 and H4 anti-targets 
Figure 2. Assessment of histamine H3 receptor Gq-coupled pharmacological assay using the IP1 accumulation 
assay measured by the HTRF IP-One assay. Concentration-dependent responses to histamine in H3 receptor 
expressing tsA201 cells transfected with (black) and without (grey) Gqi5. Data are means ± S.D. of a single 
representative experiment performed in triplicate. Two additional experiments gave similar results.
Figure 3. IP-One assay concentration-response curves. (A) Concentration-inhibition curves of the five 
identified neutral antagonists in the presence of histamine (EC80 concentration). (B) Inverse agonism of 
compound 76 (no histamine added). Data are normalized to the basal level of IP1 (fold response) in ligand 
buffer and are shown as means S.D. of a single representative experiment performed in triplicate. Due to 
solubility issues the lower plateau for the concentration-response curve of compounds 46, 57 and 67 was 
constrained to the buffer value during curve fitting.
www.nature.com/scientificreports/
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Cmpd Structure IC50 (µM) pIC50 ± SEM n Ki (µM)
Affinity 
(pKi) n
Most 
similar 
ChEMBL 
ligand
ECFP-4* 
similarity
Affinity 
(pKi)
34
N
N
H
N O
N
N 0.66 6.2 ± 0.13 5 1.97 5.71 ± 0.17 5 ChEMBL 237514 0.26 6.1
35
N
N
N
N
N
3.3 5.5 ± 0.27 5 1.75 5.76 ± 0.05 4 ChEMBL 1923529 0.42 6.2
46 6.6 5.2 ± 0.37 3 6.07 5.22 ± 0.09 3 ChEMBL 2048591 0.24 7.3
57 5.2 5.3 ± 0.37 4 1.59 5.80 ± 0.14 3 ChEMBL 460313 0.37 6.9
67 8.5 5.1 ± 0.25 6 3.52 5.45 ± 0.19 3 ChEMBL 186456 0.36 5.5
76
2.7 5.6 ± 0.14 2 1.59 5.80 ± 0.05 3 ChEMBL 
65849 0.26 8.0
Inverse agonism activity 4.2 5.4 ± 0.068 3
Table 1. Identified H3 receptor ligand structures, potencies and most similar ChEMBL ligand. *ECFP-4 2D 
topological similarity.
Figure 4. (A) Radioligand competition binding assay validates hits at the H3 receptor. Representative curves 
of the competitive binding of [3H]N-α-methylhistamine (0.3 nM) in the presence of various concentrations of 
compounds. Data points are shown as the mean ± S.D. of triplicate measurements. (B) The obtained affinities 
correlate with the potencies obtained in the functional assay. The potencies of the six most potent compounds 
obtained from the IP-One assay (Functional) shown as pIC50 compared with their affinities as determined in the 
radioligand competition binding assay (Binding). All data points are shown as the mean ± S.E.M, n = 2–5.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 4829  | DOI:10.1038/s41598-017-05058-w
contain 14, 16 and 7 binding pocket residues, respectively, that differ from the target, H3 (Fig. 5A). As previously 
shown for the metabotropic glutamate receptors42, such residues represent the receptor selectivity hotspots that 
could be targeted by interactions with new ligand substitutions. Specifically, the analysis shows that selective 
analogues can be achieved by exploiting at least one H3-unique residue (V2x64, A45x52, A5x43, T6x52, M6x55 
or E7x35) or a combination of residues that are conserved between some, but not all receptor subtypes (M1x39, 
Y2x60, W3x28, L3x29, Y3x33, C3x36, S5x44, E4x461, Y7x35, F7x38 or W7x42). Structural comparison of the H3 
with the most homologous receptor, H4, shows that selectivity hotspots surround the pharmacophore fragments 
from all sides, except from TM3 in which all binding site residues are conserved (Fig. 5B). Hence, structure-based 
ligand optimisation of the H3 ligands obtained herein (and elsewhere) can access the receptor selectivity hotspots 
by a range of substitution vectors.
Discussion
Our crystal structure fragment-based method16 led to the identification of five neutral antagonists and one 
inverse agonist for the histamine H3 receptor. Apart from their potential therapeutic value, neutral antagonists 
are interesting for pharmacological studies as they by definition inhibit both agonists and inverse agonists43. In 
contrast, no agonists were identified herein and this is expected for structure-based techniques that use a recep-
tor template in the inactive state – we placed the fragments onto the transmembrane helix backbone of the H1 
receptor crystal structure in complex with the inverse agonist doxepin (PDB: 3RZE)44. For agonist identification 
studies, the same library fragments applied herein should instead be superposed to an active state structure, 
such as the β2-adrenoceptor-Gs protein complex45. As the ligand binding site contracts upon activation46, such a 
pharmacophore could better accommodate agonists, which are typically smaller than antagonists. The six ligands 
identified herein display four distinct scaffolds, and in particular 34, 46 and 76 were found to be novel when com-
paring to the known H3 receptor ligands in ChEMBL, which is the largest public database for bioactive drug-like 
small molecules. These could represent new chemical entries for drug discovery, and whereas we herein tested the 
commercially available analogues, it would be highly warranted to further explore these as starting points in the 
synthesis and optimization of a larger number of analogues.
This study represents the first proof-of-concept for the application of our crystal structure fragment-based 
method in a prospective virtual screening, and gave a hit rate of 8% (6/76 compounds with IC50 < 10 μM). The 
best ligand potency and affinity was 660 nM and 1.6 µM, respectively. In a recent study, Lepailleur et al. used a tra-
ditional ligand-based pharmacophore, not reporting a hit rate but leading to 41.6 nM affinity at the H3 receptor14. 
Sirci et al. combined ligand- and protein-based molecular fingerprinting methods, and achieved a very high hit 
rate, 62%, and a best affinity of 0.5 μM (which is also high affinity considering that these hits were all fragments)47. 
This suggests that there are several techniques that can lead to comparable results, and that rates are influenced by 
Figure 5. Histamine receptor subtype selectivity hotspots. (A) Sequence alignment of the non-conserved 
histamine receptor binding cavity residues that offer the most viable contact points for achieving subtype-
selective ligands. Below the consensus sequence is shown also the residue properties, which when unique for 
the target may guide the choice of ligand substitution. (B) Superposition of the H3 target (brown) with the 
most homologous receptor, H4 (green). Pharmacophore fragments are displayed as balls and sticks (cyano) and 
selectivity hotspot residues as tubes.
www.nature.com/scientificreports/
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the extent to which diverse and novel scaffolds are selected. What sets this method apart is instead the advantage 
that ligands can be identified without the requirement for previously known ligands. If such data would have 
been incorporated (beyond the E5.46x461 fragment) or the structural novelty not enforced as a filter, it can be 
expected that the hit rate and affinity would have been higher. Another advantage observed in the application of 
the crystal structure-based method to the H3 receptor target is that its inference from other (crystallized) recep-
tors yielded a larger number of pharmacophore elements – ten instead of four14 and five47, respectively. This offers 
unique opportunities to target medicinal chemistry substitutions in the ligand optimisation phase on the basis of 
crystallographic evidence.
The unique ability to infer pharmacophore elements suggests that the crystal structure-based pharmacophore 
method is likely to offer a bigger advantage when applied to other GPCR targets that lack known ligands or a 
closely homologous crystal structure. Klabunde et al. succeeded in the identification of C3a receptor ligands using 
a method based on fragments and pharmacophores48. A larger variety of studies have inferred whole scaffolds 
or ligands between targets, based on chemogenomic techniques that detect local similarities within the trans-
membrane binding pocket49–56. The ability to perform such binding pocket comparisons have greatly increased 
as an effect of the many high-quality templates in the form of GPCR crystal structures, many of which are in 
complex with ligands. In this analysis, the H3 receptor was used as a template to place residue backbone atoms 
onto transmembrane helices. This receptor displays a sequence similarity of 59% and 57% to the H1 receptor 
transmembrane bundle and the doxepin binding site (5 Å proximity), respectively. The fragments, defining the 
residue sidechains and ligand moieties, were instead inferred from a variety of aminergic receptors. For such 
SAR-borrowing it is crucial to use structure-based sequence alignments to ensure that the equivalent residues are 
correctly identified, but this is greatly complicated by a number of frequent structural distortions in GPCR heli-
ces, bulges and constrictions. Specifically, one residue, E5.46x461, in the applied fragments is located at the tip of 
a bulge in many aminergic GPCRs. We used the GPCRdb alignments, which take this into account by defining the 
corresponding residue structure/sequence positions by superposition of crystal structures, and appends a second 
correct generic residue number to the Ballesteros-Weinstein number34.
In the present study, we utilized co-transfection of the human histamine H3 receptor with the chimeric Gqi5 
protein to channel receptor signalling into the Gq pathway. Others have successfully applied this strategy in 
the attempt of developing robust Gq-directed pharmacological assays for GPCRs in general57, as well as for the 
mouse36 and human58 H3 receptor. Instead of utilizing Gq coupling for measuring calcium release we chose to 
develop an HTRF-IP1 accumulation assay that offers high sensitivity in an efficient 384-well format59. This assay 
was successfully established and showed satisfactory Z′-factors taken into consideration that it was a transient 
expression of receptor and G protein. It is to our knowledge the first demonstration of applying the IP-One Tb 
Cisbio assay on the histamine H3 receptor. Hence, with these assays we were able to confirm histamine ago-
nism and identify several novel antagonists and one inverse agonist, demonstrating a broad detection range and 
versatility.
The subsequent characterization of the most potent compounds in the radioligand competition binding 
assay provides evidence that the inhibitory activity seen in the IP-One assay was mediated via an interaction 
with the H3 receptor, as the potencies/affinities obtained in both assays generally correlate well (Fig. 4B). This 
was however not true for all the compounds, as compounds 21 and 68 were unable to compete with binding of 
[3H]N-α-methylhistamine in the binding assay despite having previously shown inhibitory activity in the IP-One 
assay. This conflicting data may be due to an interference with the IP-One assay or an unspecific event leading to 
an apparent inhibition, such as cytotoxicity. This underlines the value of validating hits after a screening with an 
assay based on another principle. Additionally, the binding assay allowed for a more precise determination of the 
compound potency rank order, as the variations in the pIC50 values from the IP-One assay was greater than the 
corresponding variation in the pKi values for the binding assay (Fig. 4B). Interestingly, some compounds (42, 44 
and 46) were unable to lower the binding of [3H]N-α-methylhistamine to non-specific binding levels, as would 
otherwise be expected for ligands competing for binding at the orthosteric site. It cannot be ruled out that the 
unprecedented number of (10) pharmacophore elements, whereof three cationic elements and four aromatic, 
allow for compounds to bind simultaneously with the radioligand, [3H]N-α-methylhistamine, which is relatively 
small. However, future studies would be needed to firmly establish if 42, 44 and 46 bind in an allosteric binding 
site or there is another explanation (e.g. a secondary binding site for the radioligand).
Conclusions and Future Perspectives. A variety of alternative approaches exist for virtual screening for 
new lead drugs and pharmacological tool compounds. This study provided the first proof-of-concept for our 
recent pharmacophore method based on crystal structure fragments. This method will benefit from more frag-
ments as the number of GPCR crystal structures increase even further, also for the same receptor in complex with 
a diversity of ligands. We are currently working to implement this method on targets with less structural informa-
tion, including orphan receptors, and the application in the wider community is facilitated by free matching of the 
fragments to any class A GPCR target in GPCRdb. Both H3 receptor inverse antagonists and (neutral) antagonists 
are of proven therapeutic value. The ligands identified herein are drug-like molecules with novel scaffolds that 
could serve as starting points for further lead optimization.
Methods
Construction of a H3 pharmacophore. A structure-based sequence alignment of the H1 and H3 receptors 
was downloaded from GPCRdb17, and a model of the H3 receptor transmembrane domain was built in Modeller60 
using the H1 crystal structure (PDB: 3RZE)44 template. The pharmacophore was designed using our previously 
described crystal structure-based pharmacophore method16, which is based on the manual annotation of a library 
of structural fragments, pairs of a receptor residue and interacting ligand moiety, from GPCR crystal structure 
complexes. Herein, we uploaded our H3 receptor model to GPCRdb17 to identify conserved residues represented 
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in this library, and to superpose the backbones of the corresponding fragments. The pharmacophore elements 
were placed using Phase61 at the highest density of the (multiple) fragment moieties. The vectors of the hydrogen 
bonding features were defined after optimization of ligand moiety – receptor residue interactions. Furthermore, 
the H3 pharmacophore was extended with an additional element not covered by the fragment library, but instead 
defined by matching reference ligands to the pharmacophore as well as docking them into a H3 structure model. 
The additional pharmacophore element represents a cationic ligand functionality that interacts with a Glu residue 
in position 5.46 × 461. This residue has been shown by mutagenesis studies be important for binding of imida-
zole- and pyridine-containing ligands, including histamine62, 63.
Preparation of reference ligand and screening databases. Histamine H3 receptor reference ligands 
were downloaded from ChEMBL64 and the IUPHAR guide to pharmacology databases4. We used only the lig-
ands with submicromolar dose-response affinity or activity values (Ki, pKi, EC50, pEC50, IC50 and pIC50), and the 
highest assay confidence scores: 8 or 9. The screening database, eMolecules plus65, was prepared with LigPrep66 
to desalt, add hydrogen atoms and generate tautomers, stereoisomers (max 32) and 3D conformations (max 10 
ring conformations). Epik and the OPLS 2005 force field were applied to generate charge states at pH: 7.0 ± 1.066. 
LigFilter was used to remove structures with reactive functional groups and match the properties (Supplementary 
Table 4) of the reference ligands67.
Pharmacophore screening and hit selection. The Phase database, containing both reference ligands 
and screening compounds, was prepared with 100 maximum conformers, up to 10 conformations per rotatable 
bond, thorough conformational sampling, conformational variation of amide bonds and a maximum relative 
energy difference of 6.0 kcal/mol. A minimum of four matching pharmacophore elements was required and a 
preference was set for partial matches involving more sites. Hits were sorted by fitness score and clustered with 
Canvas68 to select diverse representative structures. As a secondary assessment of compound structures, we used 
SiteMap69 on a H3 structure model. After the first assaying round small structure-activity relationship analyses 
were conducted and the compounds sorted into lead ligand series. The selections of analogues were based on 
substructures drawn in MarvinSketch and queried n the eMolecules database loaded into Instant JChem (Marvin 
5.12.3, 2014 and Instant JChem 6.2.0, 2014, ChemAxon, www.chemaxon.com).
Histamine receptor binding site comparison. The H1 crystal structure and updated H2–4 homology 
models were downloaded from GPCRdb17, 18. An initial alignment of all class A GPCR ligand binding pocket resi-
dues was retrieved, also from GPCRdb. This alignment was first filtered to pinpoint the receptor subtype-differing 
positions, and subsequently by structural investigation to extract only those residues that may be accessible to 
ligand substitutions (Fig. 5A).
Pharmacological assaying materials. Buffers and media for cell culturing were all purchased from 
Invitrogen (Paisley, United Kingdom) whereas non-enzymatic dissociation solution, HEPES (4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid) and additional assay buffer supplements were from Sigma-Aldrich (St. Louis, 
MO, USA). The IP-One Tb assay kit was purchased from Cisbio (Codolet, France). The human histamine H3 
DNA (Genbank accession no. AF321910.1) in a pSI expression vector was identical to a previously used one58. 
The G protein Gqi5 was a kind gift from Dr. Evi Kostenis, University of Bonn, Germany. Histamine hydrochlo-
ride and thioperamide maleate were obtained from Sigma-Aldrich and Abcam Biochemicals (Cambridge, UK), 
respectively.
Cell culture and transfections. Human tsA201 cells, a transformed HEK-293 cell line70, were cultivated 
in Dulbecco’s Modified Eagle’s Medium (DMEM) with GlutaMAX, supplemented with 10% foetal bovine serum, 
penicillin 100 U/ml and streptomycin 100 µg/ml. Subconfluent cells grown in a 100 mm dish were transfected 
with 5 μg DNA using the Polyfect transfection reagent using the protocol of the manufacturer (Qiagen, West 
Sussex, UK), however with half of the recommended PolyFect volumes. Co-transfections (ratio 4:1) were per-
formed with either constructs expressing the human histamine H3 receptor together with an empty vector and 
chimeric G protein Gqi5, respectively.
IP-One assay. We applied the highly sensitive high-throughput homogeneous time-resolved fluorescence 
(HTRF) technology71 for detection of IP-One generation using the Cisbio IP-One Tb assay kit, exactly as previ-
ously described72. In brief, on the day of assay, ligand solutions were prepared in ligand buffer (Hank’s Balanced 
Salt Solution (HBSS) containing 20 mM HEPES pH 7.4, 1 mM CaCl2, 1 mM MgCl2, 40 mM LiCl)) and added to 
the wells of a 384-well OptiPlate (PerkinElmer, Waltham, USA) in triplicates. When testing for antagonist activity 
the ligand buffer was supplemented with an EC80 concentration of histamine, and we used a final compound 
concentration of 20 µM and 2 µM for the first (virtual hits) and second (analogues) screening, respectively. Cell 
suspensions were added and incubated with ligands for 1 hour, followed by the addition of detection solution 
(IP-One Tb conjugate & Lysis Buffer +2.5% anti-IP1 cryptate Tb conjugate +2.5% IP1-d2 conjugate. 38:1:1) and 
incubation in the dark for one hour at room temperature. The plate was read on an EnVision 2104 Multilabel 
Reader (PerkinElmer) by exciting the wells with light of 340 nm and measuring the emission at 615 nm and 
665 nm. The fluorescence resonance energy transfer ratios (665 nm/615 nm) were converted to IP1 concentra-
tions by interpolating values from an IP1 standard curve generated from an IP1 calibration stock, provided by the 
manufacturer (Cisbio).
[3H]N-α-methylhistamine radioligand competition binding assay. HEK-239T cells were grown 
to 70% confluency in 150 mm cell culture dishes and transfected with 8 µg human H3 receptor using the Polyfect 
transfection reagent as previously described72. After 48 hours, cells were washed from each cell culture dish with 
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Dulbecco’s phosphate buffered saline and harvested using a cell scraper. The resulting cell suspension was then 
centrifuged and resuspended in 500 µL lysis buffer (50 mM Tris-HCl, pH 7.4). The cell lysate was centrifuged at 
16,000 g for 20 minutes at 4 °C. The resultant membrane pellets were stored at −80 °C until use. Each pellet was 
resuspended in 500 µL binding buffer (50 mM Tris-HCl, 0.5 mM EDTA, pH 7.4), homogenized and centrifuged 
at 16,000 g for 15 minutes at 4 °C, and subsequently resuspended in 15 mL of binding buffer to a desired protein 
concentration of approximately 0.2 mg/mL as determined by the method of Bradford73. The membrane solution 
(30 µg protein per well) was incubated for 90 minutes in 250 µL of binding buffer, with or without compound, 
together with 0.3 nM [3H]N-α-methylhistamine at room temperature. Non-specific binding was defined as the 
radioligand bound to membrane solution incubated with 10 µM histamine. The binding reaction was terminated 
by rapid filtration through Whatman GF/C unifilters (PerkinElmer), and washed four times with ice-cold wash 
buffer (50 mM Tris-HCl, 10 mM MgCl2, 0.1 mM EDTA, pH 7.4) using a 96-well Packard FilterMate cell harvester 
(PerkinElmer). Finally, Microscint 0 scintillation liquid (PerkinElmer) was added to the dried filters, and the 
radioactivity quantified in a Packard TopCount NXT microplate Scintillation Counter (PerkinElmer).
Data analysis. In the first (virtual) screening, hits were selected if they displayed inhibition values greater 
than 3 standard deviations above the inhibition mean of the set of tested compounds. In the second screening, 
we applied a more stringent hit criterion requiring an IC50 value lower than 10 µM. Data were analysed using 
GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA). Concentration-response curves were fitted by 
nonlinear regression to equation (1):
= +
−
+ − ∗
R R R R
1 10 (1)max
max min
IC X n(log ) H50
where X is the logarithm of the concentration, R is the response, Rmax is the maximal response, Rmin is the minimal 
response, IC50 is the concentration giving half-maximum reduction of the response, and nH is the Hill coefficient, 
which describes the steepness of the curve. IP-One assay results are reported either as raw FRET in arbitrary 
units, as IP1 concentration (nM) or as fold over basal (normalized to the basal level of IP1 in ligand buffer [IP1]/
[IP1]basal). The Z′-factors were calculated using equation (2):
′
σ σ
= −
+
−
+ −
+ −µ µ
Z 1
3 3
(2)
c c
c c
Z′ = 1 − ((3σc+ + 3σc−)/|μc+ − μc−|), where σc+ and σc− are the standard deviation of the positive control and 
the negative control, respectively, and μc+ and μc− are the mean of the positive control and the negative con-
trol, respectively. Values were determined for both agonist mode (histamine alone) and antagonist mode (hista-
mine + thioperamide) using buffer as negative control. The Z′ determination was performed on a separate plate 
(n = 10–14 for each condition) and not on the library screening plates themselves, which, however, all contained 
controls that confirmed that the assay worked.
The binding data was fitted by nonlinear regression to equation (3):
= +
−
+ −
Y Y Y Y
1 10 (3)max
max min
X logIC50
where X is the logarithm of the concentration, Y is the specific binding, Ymax is the maximal specific binding, Ymin 
is the minimal specific binding, and IC50 is the concentration giving half-maximum reduction in specific binding. 
The obtained IC50 values were converted to Ki values by the Cheng-Prusoff equation, using a published Kd value, 
0.15 nM for this receptor-radioligand pair58, 74.
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